GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

Pakistan flag Pakistan · Delayed Price · Currency is PKR
356.56
-6.79 (-1.87%)
At close: Apr 28, 2026
-12.94%
Market Cap 113.55B
Revenue (ttm) 65.90B
Net Income (ttm) 10.03B
Shares Out 318.47M
EPS (ttm) 31.48
PE Ratio 11.33
Forward PE 9.54
Dividend 17.00 (4.68%)
Ex-Dividend Date Apr 24, 2026
Volume 197,067
Average Volume 456,171
Open 360.00
Previous Close 363.35
Day's Range 355.10 - 361.00
52-Week Range 293.09 - 459.94
Beta 0.40
RSI 47.90
Earnings Date Apr 27, 2026

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan. It deals in anti-infective, dermatology, respiratory, immunology, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc. [Read more]

Industry Pharmaceuticals
Sector Healthcare
Founded 2001
Employees 1,606
Stock Exchange Pakistan Stock Exchange
Ticker Symbol GLAXO
Full Company Profile

Financial Performance

In 2025, GlaxoSmithKline Pakistan's revenue was 65.90 billion, an increase of 7.70% compared to the previous year's 61.19 billion. Earnings were 10.03 billion, an increase of 53.38%.

Financial Statements

News

There is no news available yet.